ESTRO, the European SocieTy for Radiotherapy & Oncology,supports all the Radiation Oncology professionals in their daily practice: Radiation Oncologists, Medical Physicists, Radiobiologists and RTTs (Radiation TherapisTs) and the wider oncology community. ESTRO’s mission is to promote innovation, research, and dissemination of science through its congresses, special meetings, educational courses and publications.
Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-Effects and Improve Quality of Life in Cancer Survivors
The purpose of this international study is to try to predict which patients are more likely to have side effects from radiotherapy
ESTRO 36 will take place 5-9 May 2017 in Vienna, Austria. ESTRO, the European SocieTy for Radiotherapy & Oncology, is a non-profit and scientific organisation that fosters the role of Radiation Oncology in order to improve patients’ care in the multimodality treatment of cancer.
There is previous evidence that a blood test called the RILA test can be used to predict side effects from radiotherapy. The REQUITE project is trying to confirm this in large numbers of breast, prostate and lung cancer patients. Early experiments helped to standardise the test across the three European universities where the test was being carried out: Leicester, Montpellier and Mannheim. Further testing was then carried out in over 1300 patients, with similar results being found in the three laboratories.
The REQUITE abstract: "T. Rattay, et al: Development and validation of a predictive risk model for acute skin toxicity in patients undergoing breast radiotherapy" has been accepted for poster presentation at the 15th St. Gallen International Breast Cancer Conference, Primary Therapy of Early Breast Cancer Vienna, Austria 15-18 March 2017.
Tim Rattay is investigating how clinical and genetic data can be integrated to give breast cancer patients more accurate information about their individual risk of radiation side-effects.
ESTRO is an interdisciplinary society where radiation oncologists, medical physicists, radiobiologists, brachytherapists and radiation therapists aspire to join forces with other organisations in the oncology field that share ESTRO’s vision of excellence in cancer treatment. For more information click here
The 5th REQUITE Annual Consortium Meeting will be held 20-21st June 2017 at Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain www.vhio.net. As in previous years, this will be held in conjunction with the International Radiogenomics Consortium annual meeting on 19th June.